Yardley DA, Peacock N, Daniel B, Anz B, et al. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Res Treat 2020;180:647-655.
PMID: 32060783